LIVN LivaNova PLC Ordinary Shares

XNAS 92.71 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

LIVN $92.71 —
Key stats
$92.71
52-Week Range
$49.83 – $99.38
YTD
+52.89%
IV Rank (30D)
44.98
Straddle Price
$9.75
P/C Vol Ratio
0.62
Market Cap
$5.0B
Open
$92.31
Day Range
$91.10 – $92.86
Volume
188,235
Prev Close
$89.99
Fair Value
MODEL: SHORT

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.90%
Beta vs SPY1.04
Cost of Equity (CAPM)10.65% (VRP-adj)
WACC10.52%
Volatility Risk Premium+23.4pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+8.9%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.09 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$0.1B
Return on Equity (TTM)14.3%
Book / Price26.6%
Gross Margin (TTM)67.8%
FCF Margin (TTM)8.6%
Debt / Equity0.22
Quality Score3/6 — normal (10y DCF)
Market-Implied Growth+22.0% (reverse-DCF on current price)
SMA 50$79.27 (Market Anchor value)
SMA 20 / Bollinger Mid$81.08
Bollinger Width / SMA2023.6% (drives anchor stability)
Net Debt$-0.3B
Market Cap$5B
Peers used for multiples: ABT, BSX, EW, GEHC, ISRG, MDT, PEN, SYK
60-Day Conviction
69%
20-Day Fair Value
≈ by Dec 8, 2026
$91.37
α -1.5% rank 29%
conviction
82%
40-Day Fair Value
≈ by Jan 6, 2027
$90.84
α -2.0% rank 29%
conviction
64%
60-Day Fair Value
≈ by Feb 4, 2027
$89.92
α -3.0% rank 29%
conviction
69%
MethodImplied PriceWeightDetail
DCF $46.02 22%
DDM (Gordon) n/a 0%
Peer P/E $126.33 7% median 38.5× · 8 peers
Peer EV/EBITDA $89.99 7% median 20.6× · 8 peers
Peer P/B $111.22 7% median 4.7× · 8 peers
Peer P/S $127.76 7% median 4.5× · 8 peers
Market Anchor (SMA50) $79.27 29% stability 65% (BB-width)
Options Expected (B-L 30d) $91.54 22% 21 strikes · skew +0.40
As of 2026-11-09 · updated
About
Industry (SIC)
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS (3845) · industry map
Exchange
XNAS
Market Cap
$5.0B
Employees
3,300
List Date
1993-02-10
CIK
0001639691
Last Earnings
Nov 4 before open · +17.9% vs ±10.3% expected
Next Earnings
~Feb 24, 2027 (estimated)
Headquarters
Gloucester
Homepage
https://www.livanova.com

UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan-2.59%-13.66%1.83%-3.68%7.07%8.36%-0.45%
Feb20.33%4.54%-15.12%10.86%-13.38%5.75%2.16%
Mar-3.92%5.75%-6.14%1.27%-5.85%-9.55%-3.07%
Apr15.56%-9.50%12.28%1.07%-5.20%-7.01%1.20%
May-0.62%-11.85%-7.58%-2.48%17.56%20.98%2.67%
Jun2.96%-7.93%12.79%-8.92%3.71%11.41%2.34%
Jul1.21%0.58%14.68%-9.32%-7.78%-2.84%-0.58%
Aug-5.91%-11.18%-5.14%4.28%37.05%-3.21%2.65%
Sep-5.35%-7.15%-5.32%5.97%-7.98%-4.57%-4.07%
Oct-5.47%-7.28%-6.86%-1.86%3.99%5.72%-1.96%
Nov2.77%18.41%-10.37%2.68%21.36%15.59%*8.41%
Dec8.54%-1.10%12.67%-11.44%-2.50%--1.23%
Total26.56%-36.86%-8.01%-13.19%44.43%42.47%9.23%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $81.85
SMA 50: $79.52
SMA 200: $73.65
Current: $92.72
EMA 12: $85.65
EMA 26: $82.41
MACD: 3.2391 | Signal: 1.4101
BULLISH
ADX (14): 26.26
TREND
+DI: 36.80
−DI: 9.51

Momentum Oscillators

RSI (14): 70.19
OVERBOUGHT
Stoch %K: 62.48
Stoch %D: 64.15
Williams %R: -31.16

Volume & Volatility

BB Upper: $92.50
BB Lower: $71.20
OVERBOUGHT
OBV: 14,160,352
Vol SMA 20: 736,538
Vol ROC: -48.45%
ATR: $3.59
True Range: $2.87
HV 20: 65.1%
HV 30: 54.5%
HV 60: 42.2%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before LIVN’s Nov 4 earnings report, so it doesn’t reflect the results.

LLM Stock Analysis Report

Executive Summary

BULLISH (Confidence Level: 7/10)

Key drivers:

  • Strong technical momentum, with a trending upward trajectory
  • Positive news sentiment from recent headlines in the medical technology industry
  • Low risk profile due to moderate volatility and stable beta relative to the market

Primary risks:

  • High IV rank indicating historically low volatility, which may lead to potential reversals or sharp price movements
  • Options market pricing a moderate move by expiration, potentially limiting upside

Recent news sentiment impact:

  • Recent headlines highlight positive developments in the medical technology industry, such as growth projections and new product launches
  • This news sentiment has contributed to the bullish trend seen in LIVN's stock price over the past few months

Technical Analysis

Trend Direction: Medium-term uptrend (1-3 months)

Support/Resistance Levels:

  • Lower band: $75.18
  • Middle band: $79.76
  • Upper band: $84.33
  • Breakout level: $87.50

Momentum Signals:

  • RSI: 50.82 (neutral)
  • MACD signal line crossover above -0.04, indicating bearish momentum
  • Bollinger Bands position: neutral, with price near the middle band

Volume Analysis: Volume trends indicate a moderate increase in buying interest, potentially supporting the uptrend

News & Sentiment Analysis

Recent Headlines Summary:

  • Positive news headlines from the medical technology industry, highlighting growth projections and new product launches
  • Recent articles focus on the potential of AI and remote diagnostics to drive value in the medtech sector

Sentiment Assessment: Aggregate news sentiment is positive, with a confidence level of 8/10

Catalyst Identification:

  • Upcoming earnings release date (TBD)
  • Potential regulatory approvals for new medical devices
  • Industry conferences and events highlighting advancements in AI and remote diagnostics

Risk & Volatility Assessment

Beta Interpretation: Beta of 1.02 indicates a relatively stable stock price, with movements amplifying the market's volatility

Volatility Regime: Current volatility is above average, but not excessively high

Options Market Signals:

  • IV rank: 9.1% (low), indicating historically low volatility
  • Put/call ratio: 1.38 (bearish sentiment)
  • Unusual activity: moderate volume in calls and puts, with a slight bias towards calls

Downside Protection: Support levels and risk management considerations:

  • Lower band: $75.18
  • Middle band: $79.76

Market Context & Positioning

Sector Performance: LIVN is outperforming the broader medical technology sector

Institutional Activity: Moderate institutional interest in buying, potentially supporting the uptrend

Correlation Analysis: R-squared value of 0.35 indicates a relatively high correlation with the overall market

Relative Valuation: Position within trading range:

  • Relative to its peers: slightly above average
  • Relative to its own historical performance: above average

Key Levels & Action Items

Critical Price Levels:

  • Support levels: $75.18 and $79.76
  • Resistance level: $84.33

Breakout/Breakdown Levels: Breakout level at $87.50, which could trigger a significant move

Time-Sensitive Catalysts:

  • Earnings release date (TBD)
  • Regulatory approvals for new medical devices

Risk Management:

  • Stop-loss levels: below $75.18 and above $84.33
  • Position sizing considerations: moderate position size, with potential to increase if the stock breaks out above $87.50
Generated
News
All LIVN news →
Earnings History
14 of 20 under expected move
Avg Expected Move
12.43%
Avg Actual Move
7.64%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-11-03 Pre-Market 4.67% 14.75% 3.16x Exceeded
2022-02-23 Pre-Market 15.82% 1.69% 0.11x Within
2022-05-04 Pre-Market 32.25% 1.04% 0.03x Within
2022-08-03 Pre-Market 21.68% 0.47% 0.02x Within
2022-11-02 Pre-Market 6.31% 3.08% 0.49x Within
2023-02-22 Pre-Market 9.01% 10.92% 1.21x Exceeded
2023-07-26 Pre-Market 11.81% 9.87% 0.84x Within
2023-11-01 Pre-Market 10.25% 2.02% 0.20x Within
2024-02-21 Pre-Market 15.84% 8.02% 0.51x Within
2024-05-01 Pre-Market 9.51% 12.32% 1.30x Exceeded
2024-07-31 Pre-Market 13.26% 3.70% 0.28x Within
2024-10-30 After-Close 10.62% 0.55% 0.05x Within
2025-02-25 After-Close 13.25% 0.60% 0.05x Within
2025-05-07 Pre-Market 9.74% 23.72% 2.44x Exceeded
2025-08-06 Pre-Market 11.32% 11.15% 0.98x Within
2025-11-05 Pre-Market 12.19% 5.80% 0.48x Within
2026-02-25 Pre-Market 10.86% 1.80% 0.17x Within
2026-05-06 Pre-Market 10.72% 15.05% 1.40x Exceeded
2026-08-05 Pre-Market 9.23% 8.41% 0.91x Within
2026-11-04 Pre-Market 10.33% 17.88% 1.73x Exceeded

Earnings calendar: this week’s reports with expected vs actual moves →

LIVN Options Activity & IV Rank

LIVN IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 42.4%
7-DTE IV: 54.8%
Expected Move: $9.75
7-DTE Move: $7.05
Days to Exp: 39 (2026-12-18)

Options Flow · All expiries

Call Volume: 1,460
Put Volume: 904
P/C Volume: 0.619
BULLISH
Call OI: 3,712
Put OI: 979
P/C OI: 0.264
Total OI: 4,691

ATM Options Pricing

ATM Call: $4.95
ATM Put: $4.80
Call %: 5.3%
Put %: 5.2%

Chain Summary

Chain Volume: 2,364
Chain OI: 4,691
Last Updated: 11/9/2026
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
HIGH γ vs HISTORY

Estimated net dealer gamma is at the 99th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
99%
vs own history
GEX tilt
+0.99
OI-weighted, today
Vanna tilt
+0.68
δ-sensitivity to IV
Charm tilt
-0.79
δ-decay vs time
Vanna tilt +0.68: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.79: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 11 ATM contracts, 4k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
No data
30 DTE / 10d —
— pts EXTREME
No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)45.6MediumNov 9
IV Rank (30 DTE)45.0MediumNov 9
Straddle Price (30 DTE)$9.75Nov 9
Beta Analysis

Risk Metrics

Beta: 1.1033
Alpha: 54.92%
Correlation: 0.3799
R-Squared: 14.4%
Stock Volatility: 40.0%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own LIVN
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$41.3M
0.03%
#710 of 3716-79.4%13F
Citadel Hedge fund
Ken Griffin
$32.6M
0.02%
#890 of 6285new13F
Renaissance Technologies Hedge fund
Jim Simons
$9.3M
0.01%
#1091 of 3138-38.0%13F
Rockefeller Capital Management Family office
Rockefeller family
$13K
0.00%
#3917 of 4729-1.3%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

LIVN Institutional Ownership (13F)

Filings for 2026-06-30 · 135 already for 2026-09-30
Diluted shares outstanding: 55,872,750 (as of 2026-09-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

332 filers356,403,518 shares$5.24B value637.88% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 7,565,342 $622.10M 11.88% 13.54% 2026-06-30
2 PRIMECAP Management Co 4,168,377 $342.77M 6.55% 7.46% 2026-06-30
3 FMR LLC Custodian 7,542,068 $264.75M 5.06% 13.50% 2026-06-30
4 Hood River Capital Management LLC 2,565,477 $210.96M 4.03% 4.59% 2026-06-30
5 AQR Capital Management, LLC Custodian 2,356,191 $191.02M 3.65% 4.22% 2026-06-30
6 Invesco Ltd. Custodian 3,237,319 $185.33M 3.54% 5.79% 2026-06-30
7 Artisan Partners Limited Partnership 2,224,763 $182.94M 3.49% 3.98% 2026-06-30
8 State Street Corp 2,165,863 $178.10M 3.40% 3.88% 2026-06-30
9 American Century Companies, Inc. 2,013,774 $165.59M 3.16% 3.60% 2026-06-30
10 Dimensional Fund Advisors LP Custodian 1,892,096 $144.75M 2.76% 3.39% 2026-09-30
11 Wellington Management Group LLP Custodian 1,739,167 $143.01M 2.73% 3.11% 2026-06-30
12 Geode Capital Management, LLC Custodian 1,764,751 $135.02M 2.58% 3.16% 2026-09-30
13 Vanguard Portfolio Management LLC 1,414,832 $116.34M 2.22% 2.53% 2026-06-30
14 CONGRESS ASSET MANAGEMENT CO 1,502,802 $114.96M 2.20% 2.69% 2026-09-30
15 Linden Advisors LP 72,515,000 $98.64M 1.88% 129.79% 2026-06-30
16 Greenhouse Funds LLLP 924,128 $75.99M 1.45% 1.65% 2026-06-30
17 Victory Capital Management Inc. 851,820 $70.05M 1.34% 1.52% 2026-06-30
18 EMERALD ADVISERS, LLC 787,101 $64.72M 1.24% 1.41% 2026-06-30
19 Nuveen, LLC Custodian 727,968 $59.86M 1.14% 1.30% 2026-06-30
20 Goldman Sachs Group Inc Custodian 1,195,721 $57.89M 1.11% 2.14% 2026-06-30
21 Northern Trust Corp Custodian 697,776 $57.38M 1.10% 1.25% 2026-06-30
22 Bank of America Corp Custodian 5,797,538 $55.63M 1.06% 10.38% 2026-06-30
23 Vanguard Capital Management LLC 673,334 $55.37M 1.06% 1.21% 2026-06-30
24 Charles Schwab Investment Management, Inc. 615,978 $50.65M 0.97% 1.10% 2026-06-30
25 LSV ASSET MANAGEMENT 659,328 $50.44M 0.96% 1.18% 2026-09-30
2 filers$888.08K notional
# Filer Notional Value % of Total Period
1 Citadel Advisors LLC Custodian $567.39K 63.89% 2026-06-30
2 Susquehanna International Group, LLP Custodian $320.70K 36.11% 2026-06-30
2 filers$593.03K notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $386.48K 65.17% 2026-06-30
2 IMC-Chicago, LLC Custodian $206.55K 34.83% 2026-09-30

LIVN Insider Trading (Form 4)

Latest: 2026-09-16
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-16 Anne M. Liddy Chief Legal Officer Grant (A) +6,291 RSU — EDGAR
2026-09-14 Francesco Bianchi Director Sell (S) −3,500 $78.01 -$273.0K EDGAR
2026-09-08 Brooke Story Director Sell (S) −2,300 $81.42 -$187.3K EDGAR
2026-09-02 Francesco Bianchi Director Sell (S) −1,650 $79.72 -$131.5K EDGAR
2026-08-13 Ahmet Tezel Chief Innovation Officer Mixed
Disp −8,589 · Tax −1,428 · Exer +12,692 · Sell −2,675
 — $65.26 -$319.3K EDGAR
2026-06-17 Todd C Schermerhorn Director Mixed
Exer +4,042 · Tax −486
 +3,556 $79.70 -$38.7K EDGAR
2026-06-17 James Christopher Barry Director Mixed
Tax −486 · Exer +4,042
 +3,556 $79.70 -$38.7K EDGAR
2026-06-17 Francesco Bianchi Director Mixed
Exer +4,042 · Tax −486 · Sell −1,200
 +2,356 $80.05 -$135.0K EDGAR
2026-06-17 Seng Stacy Enxing Director Mixed
Tax −486 · Exer +4,042
 +3,556 $79.70 -$38.7K EDGAR
2026-06-17 Ahmet Tezel Chief Innovation Officer Mixed
Tax −1,032 · Exer +2,965
 +1,933 $79.70 -$82.3K EDGAR
2026-06-17 Peter M Wilver Director Mixed
Exer +4,042 · Tax −486
 +3,556 $79.70 -$38.7K EDGAR
2026-06-17 Jette Nygaard-Andersen Director Grant (A) +2,383 RSU — EDGAR
2026-06-17 William A Kozy Director Mixed
Tax −682 · Exer +5,681
 +4,999 $79.70 -$54.4K EDGAR
2026-06-17 Susan M Podlogar Director Mixed
Exer +4,042 · Tax −486
 +3,556 $79.70 -$38.7K EDGAR
2026-06-17 Donald Zurbay Director Mixed
Exer +2,560 · Tax −308
 +2,252 $79.70 -$24.5K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

LIVN Insider Holdings

17 insiders · @ $92.72
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Alex Shvartsburg Chief Financial Officer 44,647 $4.14M $0 18 2026-04-01
2 William A Kozy Director 38,248 $3.55M $163.2K 21 2026-06-17
3 Stephanie Bolton President, Global Epilepsy 30,566 $2.83M $0 3 2026-04-01
4 Vladimir Makatsaria Chief Executive Officer 25,326 $2.35M $0 3 2026-04-01
5 Seng Stacy Enxing Director 15,793 $1.46M $0 11 2026-06-17
6 Todd C Schermerhorn Director 12,619 $1.17M $0 8 2026-06-17
7 Franco Poletti President, Cardiopulmonary 12,344 $1.14M $0 7 2026-04-01
8 Sharon O'Kane Director 11,304 $1.05M $58.6K 17 2025-06-17
9 Peter M Wilver Director 10,294 $954.5K $0 5 2026-06-17
10 James Christopher Barry Director 8,404 $779.2K $0 5 2026-06-17
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

LIVN Board & Officers

As of SEC filings through Sep 16, 2026

Directors 12

Officers 8

Changes in the last 10 years (48)
Aug 31, 2026Anne M. Liddy became Chief Legal Officer
Aug 1, 2026Stefano Folli became President, Cardiopulmonary
Jun 10, 2026Jette Nygaard-Andersen became a director
Jan 12, 2026The company announced the departure of Michael Damon Hutchinson as Chief Legal Officer in an SEC filing
Sep 3, 2025Donald Zurbay became a director
Jan 14, 2025Natalia Kozmina became Chief Human Resources Officer
Oct 8, 2024Susan M Podlogar became a director
Sep 10, 2024The company announced the departure of Trui Hebbelinck as Chief Human Resources Officer in an SEC filing
Aug 1, 2024Franco Poletti became President, Cardiopulmonary
May 13, 2024Ahmet Tezel became Chief Innovation Officer
Apr 2, 2024William A Kozy no longer listed as Chairman and CEO in SEC filings
Mar 1, 2024Vladimir Makatsaria became a director
Mar 1, 2024Vladimir Makatsaria became Chief Executive Officer
Mar 1, 2024Stephanie Bolton became President, Global Epilepsy
Jan 3, 2024Andrea Lynn Saia reported in an SEC filing no longer being a director
Dec 19, 2023William A Kozy first listed as Chairman and CEO in an SEC filing
Oct 6, 2023James Christopher Barry became a director
Apr 12, 2023The company announced the departure of Damien McDonald from the board in an SEC filing
Apr 12, 2023The company announced the departure of Damien McDonald as CEO in an SEC filing
Apr 3, 2023Damien McDonald first listed as a director in an SEC filing
Not reported recently (5)
  • Daniel Jeffrey Moore · Last reported as a director in an SEC filing dated Jun 5, 2024
  • Marco Dolci · Last reported as President CP in an SEC filing dated Apr 3, 2023
  • Thad Allen Huston · Last reported as Chief Financial Officer in an SEC filing dated May 27, 2020
  • Douglas John Manko · Last reported as Chief Accounting Officer in an SEC filing dated Apr 1, 2020
  • Vivid Sehgal · Last reported as CFO in an SEC filing dated Mar 14, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

LIVN Proposed Insider Sales (Form 144)

Latest: 2026-09-10
Last 30d: 0 filings  ·  Last 90d: 4 filings · $802K notice value · 3 unique filers

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Bianchi Francesco (2, $405K) · Tezel Ahmet (1, $210K) · Story Brooke (1, $187K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-09-10 Bianchi Francesco Officer 3,500 $273.0K 2026-09-10 Merrill Lynch — EDGAR
2026-09-04 Story Brooke Officer 2,300 $187.3K 2026-09-04 Merrill Lynch — EDGAR
2026-08-31 Bianchi Francesco Officer 1,650 $131.5K 2026-08-31 Merrill Lynch — EDGAR
2026-08-11 Tezel Ahmet Officer 2,675 $209.9K 2026-08-11 Merrill Lynch — EDGAR
2026-06-15 Bianchi Francesco Officer 1,200 $96.2K 2026-06-15 Merrill Lynch — EDGAR
2026-05-26 Bianchi Francesco Officer 1,800 $136.3K 2026-05-26 Merrill Lynch — EDGAR
2025-11-18 Story Brooke Director 250 $13.5K 2025-11-18 Merrill Lynch — EDGAR
2025-08-25 Bianchi Francesco Director 1,500 $84.8K 2025-08-25 Merrill Lynch — EDGAR
2024-12-11 Bianchi Francesco Director 1,250 $63.7K 2024-12-11 Merrill Lynch — EDGAR
2024-12-10 Hebbelinck Trui Officer 6,000 $301.6K 2024-12-10 Merrill Lynch — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-04 Earnings results EDGAR
2026-08-05 Earnings results EDGAR
2026-06-11 Shareholder vote results EDGAR
2026-05-06 Earnings results EDGAR
2026-02-25 Earnings results EDGAR
2026-01-14 Director or officer change EDGAR
2025-11-05 Earnings results EDGAR
2025-09-04 Director or officer change EDGAR
2025-08-06 Earnings results EDGAR
2025-06-11 Director or officer change · Shareholder vote results EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-02-25 0001639691-26-000010 EDGAR
2025-02-25 0001639691-25-000010 EDGAR
2024-02-29 0001639691-24-000021 EDGAR
2023-02-27 0001639691-23-000015 EDGAR
2022-03-01 0001639691-22-000013 EDGAR
2021-03-01 0001639691-21-000016 EDGAR
2020-03-02 0001639691-20-000018 EDGAR
2019-03-18 0001639691-19-000035 EDGAR
2018-02-28 0001639691-18-000016 EDGAR
2017-03-01 0001639691-17-000011 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-04 0001639691-26-000115 EDGAR
2026-08-05 0001639691-26-000090 EDGAR
2026-05-06 0001639691-26-000035 EDGAR
2025-11-05 0001639691-25-000150 EDGAR
2025-08-06 0001639691-25-000102 EDGAR
2025-05-07 0001639691-25-000042 EDGAR
2024-10-31 0001639691-24-000134 EDGAR
2024-08-01 0001639691-24-000109 EDGAR
2024-05-03 0001639691-24-000060 EDGAR
2023-11-01 0001639691-23-000113 EDGAR
ETF Holders
92 ETFs hold LIVN
25 shown · $966.74M total exposure · 0.16% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 IJH iShares Core S&P Mid-Cap ETF iShares (BlackRock) 0.15% $179.4M $121.4B 2026-11-06
2 AVUV Avantis U.S. Small Cap Value ETF Avantis 0.46% $146.2M $31.6B 2026-11-05
3 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.17% $131.3M $76.6B 2026-11-06
4 VXF Vanguard Extended Market ETF Vanguard 0.05% $47.5M — 2026-09-30
5 DFAT Dimensional US Targeted Value ETF Dimensional 0.15% $45.3M — 2026-11-05
6 XMMO Invesco S&P MidCap Momentum ETF Invesco 0.69% $41.5M — 2026-11-05
7 DFAS Dimensional US Small Cap ETF Dimensional 0.11% $38.6M — 2026-11-05
8 MDY State Street® SPDR® S&P MIDCAP 400® ETF Trust SPDR (State Street) 0.15% $38.3M $25.6B 2026-11-05
9 XMHQ Invesco S&P MidCap Quality ETF Invesco 0.67% $38.1M — 2026-11-05
10 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.27% $37.6M $13.9B 2026-11-06
11 IJK iShares S&P Mid-Cap 400 Growth ETF iShares (BlackRock) 0.30% $30.2M $10.2B 2026-11-06
12 SPMD State Street® SPDR® Portfolio S&P 400™ Mid Cap ETF SPDR (State Street) 0.15% $27.4M $18.3B 2026-11-05
13 VTWO Vanguard Russell 2000 ETF Vanguard 0.14% $25.0M — 2026-09-30
14 IHI iShares U.S. Medical Devices ETF iShares (BlackRock) 0.62% $24.8M $4.0B 2026-11-06
15 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.02% $17.7M — 2026-11-05
16 DFMC Dimensional US Micro Cap ETF Dimensional 0.22% $16.3M — 2026-11-05
17 VHT Vanguard Health Care ETF Vanguard 0.06% $12.8M — 2026-09-30
18 SMLF iShares U.S. Small-Cap Equity Factor ETF iShares (BlackRock) 0.31% $12.7M $4.2B 2026-11-06
19 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.37% $11.6M $3.2B 2026-11-05
20 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.07% $10.2M $13.7B 2026-11-06
21 MDYG State Street® SPDR® S&P 400™ Mid Cap Growth ETF SPDR (State Street) 0.31% $8.3M $2.7B 2026-11-05
22 IVOO Vanguard S&P Mid-Cap 400 ETF Vanguard 0.12% $7.1M — 2026-09-30
23 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.01% $6.8M $93.2B 2026-11-06
24 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.22% $6.2M — 2026-07-31
25 DUSG Dimensional US Small Cap Growth ETF Dimensional 0.31% $6.0M — 2026-11-05
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
30.80
TTM Diluted EPS
$3.01
TTM Revenue
$1.51B
TTM Net Income
$196.06M
TTM Op. Cash Flow
$237.86M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q3 '262026-09-30$393.15M$34.29M$0.11$73.66M
Q2 '262026-06-30$390.59M$108.57M$1.93$66.59M
Q1 '262026-03-31$362.26M$22.29M$0.40$15.22M
Q4 '252025-12-31$360.92M$30.91M$0.56$82.40M
Q3 '252025-09-30$357.75M$26.78M$0.49$85.06M
Q2 '252025-06-30$352.52M$27.16M$0.50$62.92M
Q1 '252025-03-31$316.86M$-327.32M$-6.01$23.97M
Q4 '242024-12-31$321.83M$55.89M$1.03$78.71M
Q3 '242024-09-30$318.12M$32.95M$0.60$50.99M
Q2 '242024-06-30$318.57M$16.33M$0.30$43.36M
Q1 '242024-03-31$294.91M$-41.94M$-0.78$9.98M
Q4 '232023-12-31$310.13M$16.34M$0.30$44.60M
Q3 2026 • period ending 2026-09-30 • filed 2026-11-04
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
30.80
P/B
3.88
P/S
3.50
EV/EBITDA
20.48
EV/Sales
3.34
ROE
14.2%
ROA
7.1%
Div Yield
0.00%
FCF Yield
4.85%
Debt/Equity
0.22
Current Ratio
—
Market Cap
$5.14B
as of 2026-11-09

LIVN vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
ABT Abbott Laboratories $190.4B 40.9 +10.0% −11.1% 20
ISRG Intuitive Surgical Inc. $160.0B 55.8 +20.5% −17.9% 18
MDT Medtronic plc $130.2B 25.4 +9.8% +7.6% 59
SYK Stryker Corporation $124.1B 34.8 +7.9% −6.2% 31
BSX Boston Scientific Corp. $62.0B 18.7 +8.9% −53.4% 22
EW Edwards Lifesciences Corp $58.7B 60.3 +14.6% +22.9% 20
GEHC GE HealthCare Technologies Inc. Common S $37.2B 17.8 +6.9% +2.0% 30
PEN Penumbra, Inc. $12.6B 80.9 +17.0% +3.8% 26
LIVN LivaNova PLC Ordinary Shares $5.0B 30.8 +11.7% +52.9% 45
Peer median $93.0B 37.8 +9.9% −2.1% 24

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
6.20M
SI % of Float
11.29%
Days to Cover
10.56
Short Vol Ratio
49.9%
Free Float
54.90M
Float %
99.6%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-07